


## AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound having the formula I:




(I)

or a stereoisomer, tautomer, or pharmaceutically acceptable salt, ~~ester, or prodrug~~ thereof, wherein

Y is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heterocyclyl, and
- (3) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) -N(R<sup>1x</sup>)-,
- (3) -(CH<sub>2</sub>)<sub>m</sub>-C(R<sup>2x</sup>, R<sup>3x</sup>)-N(R<sup>1x</sup>)-,
- (4) -O-,
- (5) -S-,
- (6) -SO-,
- (7) -SO<sub>2</sub>-,
- (8) -C(R<sup>2x</sup>, R<sup>3x</sup>)-, and
- (9) ,  
where the piperazine ring is shown as a six-membered ring with two nitrogen atoms at the 1 and 4 positions, with single bonds extending from each nitrogen.

wherein R<sup>1x</sup>, R<sup>2x</sup>, and R<sup>3x</sup> are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (c) substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkenyl,

- (d) substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub>-alkynyl,
- (e) substituted or unsubstituted aryl,
- (f) substituted or unsubstituted heterocyclyl,
- (g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R<sub>1</sub> is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) -COOH,
- (4) halo,
- (5) -OR<sup>1t</sup>, and
- (6) -NHR<sup>1t</sup>,


wherein R<sup>1t</sup> is H or C<sub>1</sub>-C<sub>6</sub>-alkyl;

R<sub>2</sub> is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heteroaryl, and

W is selected from the group consisting of

- (1) -N(R<sup>1w</sup>, R<sup>2w</sup>), and



wherein R<sup>1w</sup> and R<sup>2w</sup> are selected from the group consisting of

- (a) substituted or unsubstituted aryl,
- (b) substituted or unsubstituted heterocyclyl, and
- (c) substituted or unsubstituted heteroaryl,

Z is selected from the group consisting of

- (a) -O-,
- (b) -NR<sup>z</sup>-,
- (c) -S-,

- (d) -SO-,
- (e) -SO<sub>2</sub>-, and
- (f) -CH<sub>2</sub>-,

wherein R<sup>z</sup> is H or substituted or unsubstituted alkyl group; and

R<sup>4w</sup> is selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (c) -COOR<sup>5w</sup>,
- (d) -CONH<sub>2</sub>,
- (e) -OR<sup>5w</sup>, and
- (f) -NHR<sup>5w</sup>,

wherein R<sup>5w</sup> is H or C<sub>1</sub>-C<sub>6</sub>-alkyl; and r is 0, 1, or 2;


with the proviso that when R<sub>2</sub> is phenyl independently substituted with one to five substituents selected from hydrogen, cycloalkyl, heterocycloalkyl, halo, nitro, amino, sulphonamido, or alkylsulphonylamino, R<sub>1</sub> is hydrogen, haloalkyl, alkyl, or halo, and X is NR<sup>1x</sup>, then Y is substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocyclyl.

2. (Previously presented) The compound of claim 1, wherein

Y is selected from the group consisting of


- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heterocyclyl, and
- (3) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) -N(R<sup>1x</sup>)-,
- (3) -(CH<sub>2</sub>)<sub>m</sub>-C(R<sup>2x</sup>, R<sup>3x</sup>)-N(R<sup>1x</sup>)-, and
- (4) ,

wherein R<sup>1x</sup>, R<sup>2x</sup>, R<sup>3x</sup> are independently H or substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl; and

W is selected from the group consisting of



wherein Z is -O- or -NR<sup>Z</sup>-, wherein R<sup>4w</sup> is H or substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl.


3. (Original) The compound of claim 1, wherein

Y is selected from the group consisting of

- (1) substituted or unsubstituted heterocyclyl,
- (2) substituted or unsubstituted heteroaryl;


X is selected from the group consisting of

- (1) a direct link,
- (2) -N(R<sup>1x</sup>)-,
- (3) -(CH<sub>2</sub>)<sub>m</sub>-C(R<sup>2x</sup>, R<sup>3x</sup>)-N(R<sup>1x</sup>)-, and



wherein R<sup>1x</sup>, R<sup>2x</sup>, R<sup>3x</sup> are independently H or substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl; and

W is selected from the group consisting of



wherein Z is -O- or -NR<sup>Z</sup>-, wherein R<sup>4w</sup> is H or substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl.


4. (Original) The compound of claim 1, wherein

Y is substituted or unsubstituted aryl;

X is selected from the group consisting of


- (1) a direct link,
- (2) -N(R<sup>1x</sup>)-,

(3)  $-(\text{CH}_2)_m-\text{C}(\text{R}^{2x}, \text{R}^{3x})-\text{N}(\text{R}^{1x})-$ , and



wherein  $\text{R}^{1x}$ ,  $\text{R}^{2x}$ ,  $\text{R}^{3x}$  are independently H or substituted or unsubstituted  $\text{C}_1\text{-C}_6$ -alkyl; and

W is selected from the group consisting of



wherein Z is -O- or -NR<sup>Z</sup>-, wherein  $\text{R}^{4w}$  is H or substituted or unsubstituted  $\text{C}_1\text{-C}_6$ -alkyl.


5. (Previously presented) The compound of claim 1, wherein

X is selected from the group consisting of

(1) a direct link,


(2)  $-\text{N}(\text{R}^{1x})-$ ,

(3)  $-(\text{CH}_2)_m-\text{C}(\text{R}^{2x}, \text{R}^{3x})-\text{N}(\text{R}^{1x})-$ , and



wherein  $\text{R}^{1x}$ ,  $\text{R}^{2x}$ ,  $\text{R}^{3x}$  are independently H or substituted or unsubstituted  $\text{C}_1\text{-C}_6$ -alkyl; and

W is selected from the group consisting of



wherein Z is -O- or -NR<sup>Z</sup>-, wherein  $\text{R}^{4w}$  is H or substituted or unsubstituted  $\text{C}_1\text{-C}_6$ -alkyl.

6. (Original) The compound of claim 1, wherein


Y is selected from the group consisting of

(1) substituted or unsubstituted heterocyclyl,

(2) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of


- (1) a direct link,
- (2)  $-N(R^{1x})-$ ,
- (3)  $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$ , and



wherein  $R^{1x}$ ,  $R^{2x}$ ,  $R^{3x}$  are independently H or substituted or unsubstituted  $C_1-C_6$ -alkyl;

$R_2$  is substituted or unsubstituted aryl; and

W is




wherein Z is -O- or -NH-.

7. (Original) The compound of claim 1, wherein

Y is substituted or unsubstituted aryl;

X is selected from the group consisting of


- (1) a direct link,
- (2)  $-N(R^{1x})-$ ,
- (3)  $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$ , and



wherein  $R^{1x}$ ,  $R^{2x}$ ,  $R^{3x}$  are independently H or substituted or unsubstituted  $C_1-C_6$ -alkyl;


$R_2$  is substituted or unsubstituted aryl; and

W is



wherein Z is -O- or -NH-.


8. (Previously presented) The compound of claim 1, wherein X is selected from the group consisting of

- (1) a direct link,
- (2)  $-N(R^{1x})-$ ,
- (3)  $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$ , and
- (4) ,

wherein  $R^{1x}$ ,  $R^{2x}$ ,  $R^{3x}$  are independently H or substituted or unsubstituted  $C_1$ - $C_6$ -alkyl;


$R_2$  is substituted or unsubstituted aryl; and

W is



wherein Z is -O- or -NH-.


9. (Previously presented) The compound of claim 1, having the formula II:




wherein Y is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heterocyclyl, and
- (3) substituted or unsubstituted heteroaryl; and

X is selected from the group consisting of

- (1) a direct link,
- (2)  $-N(R^{1x})-$ ,
- (3)  $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$ , and
- (4)  .


10. (Original) The compound of claim 1, having the formula II:




(II)

wherein Y and X, taken together, are selected from the group consisting of







11. (Original) The compound of claim 1, having the formula II:




wherein Y and X, taken together, are selected from the group consisting of




12. (Original) The compound of claim 1, having the formula II:



wherein, Y and X, taken together, are selected from the group consisting of




13. (Previously presented) The compound of claim 1, having the formula III:



wherein R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) -COOR<sup>1t</sup>,
- (4) -CONH<sub>2</sub>,
- (5) -OR<sup>1t</sup>, and
- (6) -NHR<sup>1t</sup>.


14. (Previously presented) The compound of claim 1, having the formula IV:



(IV)

wherein R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> are selected from the group consisting of

- (1) H,
  - (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
  - (3) -COOR<sup>1t</sup>,
  - (4) -CONH<sub>2</sub>
  - (5) -OR<sup>1t</sup>, and
  - (6) -NHR<sup>1t</sup>.
15. (Previously presented) The compound of claim 1, having the formula V:



(V)

wherein R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) -COOR<sup>1t</sup>,
- (4) -CONH<sub>2</sub>
- (5) -OR<sup>1t</sup>, and

(6)  $\text{-NHR}^{1t}$ ; and

$\text{R}^{2a}$  and  $\text{R}^{2b}$  are selected from the group consisting of


- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) halo,
- (4)  $\text{-(CH}_2\text{)}_q\text{-N(R}^{2c}, \text{R}^{2d}\text{)}$ ,
- (5)  $\text{-(CH}_2\text{)}_q\text{-N(R}^{2c}, \text{R}^{2d}\text{)COR}^{2e}$ ,
- (6)  $\text{-(CH}_2\text{)}_q\text{-OR}^{2e}$ ,
- (7)  $\text{-(CH}_2\text{)}_q\text{-OCOR}^{2e}$ ,
- (8)  $\text{-(CH}_2\text{)}_q\text{-OCOOR}^{2e}$ ,
- (9)  $\text{-(CH}_2\text{)}_q\text{-COOR}^{2e}$ ,
- (10)  $\text{-(CH}_2\text{)}_q\text{-CONR}^{2c}$ ,
- (11)  $\text{-CN}$ ,
- (12)  $\text{-NO}_2$ ,
- (13)  $\text{-SO}_2\text{NH}_2$ ,
- (14)  $\text{-NHSO}_2\text{CH}_3$ , and
- (15)  $\text{-SO}_2\text{R}^{2f}$ ,

wherein  $\text{R}^{2c}$ ,  $\text{R}^{2d}$ ,  $\text{R}^{2e}$ , and  $\text{R}^{2f}$  are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted phenyl; and


$q$  is 0, 1, 2, 3, or 4.

16. (Original) The compound of claim 1, having the formula VI:




(VI)

wherein R<sub>2</sub> is selected from the group consisting of




17. (Previously presented) The compound of claim 1, having the formula VII:



(VII)

wherein R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, and R<sub>10</sub> are selected from the group consisting of

- (1) H,
  - (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
  - (3) -COOR<sup>1t</sup>,
  - (4) -CONH<sub>2</sub>
  - (5) -OR<sup>1t</sup>, and
  - (6) -NHR<sup>1t</sup>.
18. (Original) The compound of claim 1, having the formula VIII:




(VIII)

wherein R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) -COOR<sup>1t</sup>,
- (4) -CONH<sub>2</sub>,
- (5) -OR<sup>1t</sup>, and
- (6) -NHR<sup>1t</sup>.

19. (Original) The compound of claim 1, having the formula IX:



(IX)

wherein R<sup>1a</sup> and R<sup>1b</sup> are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) halo,
- (4)  $-(CH_2)_q-N(R^{2c}, R^{2d})$ ,
- (5)  $-(CH_2)_q-N(R^{2c}, R^{2d})COR^{2e}$ ,
- (6)  $-(CH_2)_q-OR^{2e}$ ,
- (7)  $-(CH_2)_q-OCOR^{2e}$ ,
- (8)  $-(CH_2)_q-OCOOR^{2e}$ ,
- (9)  $-(CH_2)_q-COOR^{2e}$ ,
- (10)  $-(CH_2)_q-CONR^{2c}$ ,
- (11) -CN,
- (12) -NO<sub>2</sub>,
- (13) -SO<sub>2</sub>NH<sub>2</sub>,
- (14) -NHSO<sub>2</sub>CH<sub>3</sub>, and
- (15) -SO<sub>2</sub>R<sup>2f</sup>,

wherein R<sup>2c</sup>, R<sup>2d</sup>, R<sup>2e</sup>, and R<sup>2f</sup> are selected from the group consisting of


- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted phenyl; and



wherein R<sub>7</sub> is selected from the group consisting of


- (1) H,
- (2) substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl,
- (3) -COOR<sup>1t</sup>,
- (4) -CONH<sub>2</sub>,
- (5) -OR<sup>1t</sup>, and
- (6) -NHR<sup>1t</sup>.

20. (Original) The compound of claim 1, having the formula X:




(X)

wherein R<sub>2</sub> is selected from the group consisting of




21. (Original) The compound of claim 1, having the formula XI:




(XI)

wherein R<sup>2g</sup> is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) -CONHR<sup>2h</sup>,
- (4) -CON(R<sup>2h</sup>)-(CH<sub>2</sub>)<sub>2-3</sub>-N(R<sup>2h</sup>, R<sup>2i</sup>),
- (5) -COR<sup>2j</sup>,
- (6) -CO<sub>2</sub>R<sup>2j</sup>,
- (7) -COC<sub>1</sub>-C<sub>6</sub>-alkyl-CO<sub>2</sub>H,
- (8) -CH<sub>2</sub>-OC(=O)R<sup>2i</sup>,
- (9) -CH<sub>2</sub>-OC(=O)NHCHR<sup>2i</sup>CO<sub>2</sub>R<sup>2j</sup>,
- (10) -P(=O)(OR<sup>2k</sup>, OR<sup>2p</sup>),

- (11) , and


- (12) ,

wherein R<sup>2h</sup>, R<sup>2i</sup>, R<sup>2j</sup>, R<sup>2k</sup>, and R<sup>2p</sup> are selected from the group consisting of

- (a) H,

- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted aryl.

22. (Original) The compound of claim 1, having the formula XII:



(XII)

wherein R<sup>2g</sup> is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) -CONHR<sup>2h</sup>,
- (4) -CON(R<sup>2h</sup>)-(CH<sub>2</sub>)<sub>2-3</sub>-N(R<sup>2h</sup>, R<sup>2i</sup>),
- (5) -COR<sup>2j</sup>,
- (6) -CO<sub>2</sub>R<sup>2j</sup>,
- (7) -COC<sub>1</sub>-C<sub>6</sub>-alkyl-CO<sub>2</sub>H,
- (8) -CH<sub>2</sub>-OC(=O)R<sup>2i</sup>,
- (9) -CH<sub>2</sub>-OC(=O)NHCHR<sup>2i</sup>CO<sub>2</sub>R<sup>2j</sup>,
- (10) -P(=O)(OR<sup>2k</sup>, OR<sup>2p</sup>),

- (11) , and

- (12) ,

wherein R<sup>2h</sup>, R<sup>2i</sup>, R<sup>2j</sup>, R<sup>2k</sup>, and R<sup>2p</sup> are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted aryl.

23. (Currently amended) A composition, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier ~~and an amount of a compound of Claim 1 effective to inhibit phosphatidylinositol (PI) 3-kinase activity in a human or animal subject when administered thereto.~~

24. (Currently amended) The composition of Claim 23 further comprising at least one additional agent for the treatment of breast cancer.

25. (Currently amended) The composition of Claim 24, wherein the at least one additional agent for the treatment of breast cancer is selected from irinotecan, topotecan, gemcitabine, gleevec, herceptin, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, tamoxifen, CPT 11, and trastuzumab.

26. (Currently amended) A method for treating ~~a condition by modulation of phosphatidylinositol (PI) 3-kinase activity~~ breast cancer comprising administering to a ~~human or animal~~ subject in need of such treatment an effective amount of a compound of Claim 1.

27. (Original) The method of Claim 26, wherein the compound has an IC<sub>50</sub> value of less than about 20 µM in a cell proliferation assay.

28-30. (Canceled)

31. (Currently amended) The method of Claim ~~[[30]]~~ 26 further comprising administering to the human or animal subject at least one additional agent for the treatment of breast cancer.

32. (Currently amended) The method of Claim 31, wherein the at least one additional agent for the treatment of breast cancer is selected from irinotecan, topotecan, gemcitabine, gleevec, herceptin, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine,

cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, tamoxifen, CPT 11, and trastuzumab.


33-36. (Canceled)

37. (Previously presented) A compound of Claim 1, wherein R<sub>2</sub> is hydroxy-substituted phenyl.

38. (Previously presented) A compound of Claim 1, wherein R<sub>2</sub> is substituted or unsubstituted pyridinyl.

39. (Previously presented) A compound of Claim 1, wherein R<sub>2</sub> is substituted or unsubstituted pyrimidinyl.

40. (Previously presented) A compound of Claim 1, wherein W is



41. (Previously presented) A compound of Claim 40, wherein R<sup>4w</sup> is H, r is 1, and Z is O.

42. (Previously presented) A compound of Claim 1, wherein Y is substituted or unsubstituted heterocyclyl.

43. (Previously presented) A compound of Claim 1, wherein X is a O and Y is substituted or unsubstituted heterocyclyl.

44. (Previously presented) A compound of Claim 1, wherein X is a direct link and Y is substituted or unsubstituted heterocyclyl.

45. (Previously presented) A compound of Claim 40, wherein R<sup>4w</sup> is H, r is 1, Z is O, Y is substituted or unsubstituted heterocyclyl, R<sub>1</sub> is H, and R<sub>2</sub> is substituted or unsubstituted heteroaryl.

46. (Previously presented) A compound of Claim 40, wherein R<sup>4w</sup> is H, r is 1, Z is O, X is O or a direct link, Y is substituted or unsubstituted heterocyclyl, R<sub>1</sub> is H, and R<sub>2</sub> is substituted or unsubstituted heteroaryl.